1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane is a synthetic organic compound, not a naturally occurring one. It's likely a hypothetical molecule that doesn't have any specific significance in research.
Here's why:
* **The Structure:** The name suggests a cyclohexane ring with bromine atoms at positions 1 and 2, and a 1,2-dibromoethyl group attached at position 4. This structure is highly likely to be unstable due to steric hindrance from the bulky bromine atoms.
* **Synthesis:** Synthesizing this compound would be extremely difficult and likely not be a high priority for most research.
* **Lack of Functionality:** The molecule doesn't possess any obvious functionalities that would make it particularly interesting for research.
**Important Note:** It's important to consider that the name may be a result of a typo or misunderstanding. If you have a specific context where this compound is mentioned, please provide more details, and I can offer a more informed answer.
**In general, research focuses on compounds that are: **
* **Naturally occurring:** Many important compounds are found in nature, like drugs, antibiotics, and natural products.
* **Possessing interesting properties:** Researchers look for compounds with biological activity, unique reactivity, or specific physical properties.
* **Synthetically accessible:** Compounds can only be studied if they can be synthesized or isolated.
If you are interested in researching organic compounds, it's essential to consider these factors and focus on molecules that are likely to be relevant and impactful.
1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane: a flame retardant and androgen receptor agonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 18728 |
CHEMBL ID | 375107 |
SCHEMBL ID | 332771 |
MeSH ID | M0506828 |
Synonym |
---|
1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane |
3322-93-8 |
NCGC00091838-01 |
einecs 222-036-8 |
ccris 3743 |
citex bcl 462 |
vinylcyclohexene tetrabromide |
hsdb 6146 |
brn 1927455 |
saytex bcl 462 |
cyclohexane, 1,2-dibromo-4-(1,2-dibromoethyl)- |
4-(1,2-dibromoethyl)-1,2-dibromocyclohexane |
1-(1,2-dibromoethyl)-3,4-dibromocyclohexane |
bdbm50199965 |
CHEMBL375107 , |
MLS002454355 |
smr001371982 |
FT-0666491 |
NCGC00091838-02 |
HMS3039D13 |
unii-502d5q149t |
3-05-00-00093 (beilstein handbook reference) |
bch cyclohexane compound |
502d5q149t , |
dtxsid8024947 , |
NCGC00258523-01 |
tox21_200970 |
cas-3322-93-8 |
dtxcid204947 |
AKOS015919789 |
1,2-dibromo-4-(1,2-dibromoethyl)-cyclohexane |
c8h12br4 |
SCHEMBL332771 |
1-(1,2-dibromoethyl)-3,4-dibromocyclohexane [hsdb] |
PQRRSJBLKOPVJV-UHFFFAOYSA-N |
mfcd00086864 |
DS-17528 |
Q20054503 |
F11583 |
AB89760 |
CS-0186287 |
PD179167 |
1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane (tbech) |
SY102311 |
Excerpt | Reference | Relevance |
---|---|---|
" Yet toxicological effects are evident at low exposure concentrations: DBE-DBCH is a proven endocrine disruptor of sex and thyroid hormone pathways, with in vivo toxic effects on reproductive, metabolic, and other endpoints." | ( A review of 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane in the environment and assessment of its persistence, bioaccumulation and toxicity. Bodnaryk, A; Fernie, KJ; Fry, M; Letcher, RJ; Marteinson, SC; Marvin, C; Riddell, N; Tomy, GT, 2021) | 1 |
Excerpt | Reference | Relevance |
---|---|---|
" The results indicate that use of the generally accepted standard OECD soil may overestimate accumulation of organic contaminants by earthworms, due to high bioavailability of the contaminants and/or weight loss of the worms in it." | ( Accumulation of polybrominated diphenyl ethers, hexabromobenzene, and 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane in earthworm (Eisenia fetida). Effects of soil type and aging. Andersson, PL; Asamoah, RK; Danielsson, C; Nyholm, JR; van der Wal, L, 2010) | 0.59 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 31.6228 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 39.8107 | 0.0251 | 20.2376 | 39.8107 | AID893 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 39.8107 | 0.0251 | 20.2376 | 39.8107 | AID893 |
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 50.1187 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
interleukin 8 | Homo sapiens (human) | Potency | 74.9780 | 0.0473 | 49.4806 | 74.9780 | AID651758 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 27.1672 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
TDP1 protein | Homo sapiens (human) | Potency | 20.5962 | 0.0008 | 11.3822 | 44.6684 | AID686979 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 60.8199 | 0.0007 | 14.5928 | 83.7951 | AID1259392 |
AR protein | Homo sapiens (human) | Potency | 12.9886 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID1259381; AID743040 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 25.1189 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 39.8107 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 27.8579 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 15.2773 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 68.2410 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 36.5578 | 0.0008 | 17.5051 | 59.3239 | AID1159531 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 56.4105 | 0.0015 | 30.6073 | 15,848.9004 | AID1224848; AID1224849; AID1259403 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 29.7656 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982; AID720659 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 44.6684 | 0.0002 | 29.3054 | 16,493.5996 | AID588514 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 50.1187 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 54.6991 | 0.0237 | 23.2282 | 63.5986 | AID743222 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 38.7089 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895; AID1259385 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 26.2678 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
serine-protein kinase ATM isoform a | Homo sapiens (human) | Potency | 22.3872 | 0.7079 | 25.1119 | 41.2351 | AID485349 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 35.4813 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 22.3872 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 44.8735 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 19.9526 | 0.0398 | 16.7842 | 39.8107 | AID995 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 66.8242 | 0.0006 | 27.2152 | 1,122.0200 | AID651741 |
lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 31.6228 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
geminin | Homo sapiens (human) | Potency | 18.3564 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 15.8489 | 0.0200 | 10.7869 | 31.6228 | AID912 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 76.5677 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 17.7828 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Androgen receptor | Homo sapiens (human) | IC50 (µMol) | 0.0427 | 0.0000 | 0.8753 | 10.0000 | AID274427 |
Androgen receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.1630 | 0.0010 | 1.9794 | 14.1600 | AID274425 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID274428 | Activity against human androgen receptor expressed in HepG2 cells assessed as reduction in luciferase signal in presence of 100 uM flutamide at 1 uM after 40 hrs | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25 | Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist. |
AID274425 | Displacement of androgen fluormone from rat androgen receptor | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25 | Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist. |
AID274426 | Activity against human androgen receptor expressed in HepG2 cells assessed as activation of luciferase reporter gene at 1 uM | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25 | Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist. |
AID274429 | Activity against human androgen receptor expressed in HepG2 cells assessed as renilla reporter gene activation in presence of 1 nM DHT at 1 uM after 40 hrs | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25 | Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist. |
AID274427 | Activity against human androgen receptor expressed in HepG2 cells assessed as luciferase reporter gene activation | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25 | Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist. |
AID274424 | Displacement of androgen fluormone from androgen receptor at 100 uM | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25 | Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (17.65) | 29.6817 |
2010's | 21 (61.76) | 24.3611 |
2020's | 7 (20.59) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.40) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (2.94%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 33 (97.06%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |